ABBEXA LTDActive

Company number 08475531Private limited companyIncorporated 2013

Key figures

£2,550,212+24.7%
Net assets 2024/25
+60.8%
Average annual growth 2019/20–2024/25
01 m2 m3 m2019/202020/212021/222022/232023/242024/25

Like most small UK companies, ABBEXA LTD does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
02 m4 m2019/202020/212021/222022/232023/242024/25
Filed accounts2019/20–2024/25
2020/212021/222022/232023/242024/25
Cash at bank and in hand162,683439,815502,242381,671326,769
Total assets1,145,3691,515,0672,691,0282,942,4433,021,104
Total liabilities947,631996,6581,767,3881,413,3621,054,852
Net assets / total equity482,069884,2741,314,1372,044,9212,550,212
Average number of employees1212161822

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: ABBEXA LTD

Company

ABBEXA LTD is a private limited company registered with Companies House under company number 08475531. It was incorporated on 5 Apr 2013. Its status is active. The registered office is in Cambridge (CB4). Its nature of business (SIC 2007) is research and experimental development on biotechnology (72110).

Accounts

The latest accounts in the database are for 2024/25 (period ending 30 Apr 2025); the company files small company accounts (filleted). Net assets were £2,550,212, up 24.7% on the previous year. Cash at bank and in hand was £326,769. Total assets were £3,021,104 and total liabilities £1,054,852. The company had an average of 22 employees. Figures are available for 6 financial years (2019/20–2024/25).

Control and charges

2 persons with significant control are registered. 1 of 2 registered charges are outstanding.

Filing deadlines

The next accounts are due by 31 Jan 2027. The next confirmation statement is due by 3 Mar 2027.